ERIS Overzicht aandelen
Eris Lifesciences Limited levert, samen met haar dochterondernemingen, formuleringen van binnenlandse merken voor chronische en subchronische therapieën in India.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
Eris Lifesciences Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹1,347.15 |
| 52 Week Hoogtepunt | ₹1,522.05 |
| 52 Week Laag | ₹809.15 |
| Bèta | 0.31 |
| 11 maand verandering | -0.26% |
| 3 maanden verandering | 24.86% |
| 1 Jaar Verandering | 54.31% |
| 33 jaar verandering | 65.23% |
| 5 jaar verandering | 223.45% |
| Verandering sinds IPO | 123.97% |
Recent nieuws en updates
Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next
Oct 30
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Oct 15Recent updates
Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next
Oct 30A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Oct 15Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why
Sep 19Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%
Sep 03Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)
Jul 13Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Rendement voor aandeelhouders
| ERIS | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | 4.3% | 2.6% | 2.3% |
| 1Y | 54.3% | 59.1% | 37.9% |
Rendement versus industrie: ERIS presteerde slechter dan de Indian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 59.1 % opleverde.
Rendement versus markt: ERIS overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van 37.9 %.
Prijsvolatiliteit
| ERIS volatility | |
|---|---|
| ERIS Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.4% |
| 10% least volatile stocks in IN Market | 4.0% |
Stabiele aandelenkoers: ERIS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van ERIS is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2007 | 3,620 | Amit Bakshi | www.eris.co.in |
Eris Lifesciences Limited levert, samen met haar dochterondernemingen, binnenlandse merkformuleringen voor chronische en subchronische therapieën in India. Het bedrijf biedt verschillende merkformuleringen aan in verschillende therapeutische gebieden, zoals anti-diabetes, cardiovasculair, voeding, dermatologie, neurowetenschappen, gynaecologie, nefrologie en oncologie, evenals centraal zenuwstelsel, gezondheid van vrouwen en vitaminen/mineralen/nutriënten. Het bedrijf levert ook diensten voor patiëntenzorg, waaronder ambulante bloeddrukmetingen, ambulante elektrocardiogrammetingen, systemen voor continue glucosecontrole, slaaponderzoek en oplossingen voor prenatale zorg.
Eris Lifesciences Limited Samenvatting
| ERIS fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹183.35b |
| Inkomsten(TTM) | ₹3.48b |
| Inkomsten(TTM) | ₹24.85b |
52.6x
Koers/Winstverhouding7.4x
P/S-verhoudingIs ERIS overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ERIS resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹24.85b |
| Kosten van inkomsten | ₹5.90b |
| Brutowinst | ₹18.95b |
| Overige uitgaven | ₹15.47b |
| Inkomsten | ₹3.48b |
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 25.60 |
| Brutomarge | 76.25% |
| Nettowinstmarge | 14.02% |
| Schuld/Eigen Vermogen Verhouding | 84.8% |
Hoe presteerde ERIS op de lange termijn?
Bekijk historische prestaties en vergelijking